Long-term Functioning of Allogeneic Islets in Subcutaneous Tissue Pretreated With a Novel Cyclic Peptide Without Immunosuppressive Medication

Transplantation. 2018 Mar;102(3):417-425. doi: 10.1097/TP.0000000000001923.

Abstract

Background: There exists a need for a minimally invasive method of islet transplantation without immunosuppressive drugs for the treatment of type 1 diabetes.

Methods: In diabetic August Copenhagen Irish rats, an agarose rod containing the cyclic oligopeptide SEK-1005 (agarose-SEK rod) was implanted at 2 dorsal subcutaneous sites. Then these rods were removed, and 1500 islets of Langerhans isolated from Fischer 344 rats were transplanted into each of the pockets.

Results: Ten days after implantation of agarose-SEK rods, vascularized pockets were present. Nonfasting blood glucose levels confirmed long-term survival of the allogeneic islet grafts, without immunosuppressive therapy, in 8 of 10 recipients. Flow cytometry and gene expression analyses were performed to investigate the mechanisms underlying graft acceptance. Agarose-SEK rod implantation led to the formation of granulomatous tissue containing regulatory T cells that suppressed immune reactions against the allogeneic islet grafts.

Conclusions: These results indicate that the use of an agarose-SEK rod to prevascularize a subcutaneous site may be a useful method for achieving successful allogeneic islet transplantation without immunosuppression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Immunosuppressive Agents / pharmacology*
  • Islets of Langerhans / physiology*
  • Islets of Langerhans Transplantation*
  • Male
  • Peptides, Cyclic / pharmacology*
  • Rats
  • Rats, Inbred ACI
  • Rats, Inbred F344
  • Subcutaneous Tissue / blood supply*
  • Transplantation, Homologous

Substances

  • Immunosuppressive Agents
  • Peptides, Cyclic
  • SEK 1005